Investigating the Safety and Efficacy of the Synthetic Drug Herbix on Immune Responses Involved in the Treatment of a Mouse Model of Herpes Simplex Virus

1. James C, Harfouche M, Welton NJ, Turner KM, Abu-Raddad LJ, Gottlieb SL, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020;98(5):315.
2. Zhu S, Viejo-Borbolla A. Pathogenesis and virulence of herpes simplex virus. Virulence. 2021;12(1):2670-2702.
3. Koujah L, Suryawanshi RK, Shukla D. Pathological processes activated by herpes simplex virus-1 (HSV-1) infection in the cornea. Cell Mol Life Sci. 2019;76(3):405-419.
4. Whitford AL, Cliffe AR. Key questions on the epigenetics of herpes simplex virus latency. Plos Pathogens. 2022;18(6):1010587.
5. St. Leger AJ, Koelle DM, Kinchington PR, Verjans GMG. Local immune control of latent herpes simplex virus type 1 in ganglia of mice and man. Front Immunol. 2021;12:723809.
6. Artusi S, Ruggiero E, Nadai M, Tosoni B, Perrone R, Ferino A, et al. Antiviral activity of the G-quadruplex ligand TMPyP4 against Herpes Simplex Virus-1. Viruses. 2021;13(2):196.
7. Pisitpayat P, Jongkhajornpong P, Lekhanont K, Nonpassopon M. Role of Intravenous Acyclovir in Treatment of Herpes Simplex Virus Stromal Keratitis with Ulceration: A Review of 2 Cases. Am J Case Rep 2021;22:930467-1.
8. Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ. Genetically engineered HSV in the treatment of glioma: a review. Rev Med virol. 2000;10(1):17-30.
9. Stanberry LR. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes. 2004;11:161A-9
10. Bag P, Chattopadhyay D, Mukherjee H, Ojha D, Mandal N, Sarkar MC, et al. Anti-herpes virus activities of bioactive fraction and isolated pure constituent of Mallotus peltatus: an ethnomedicine from Andaman Islands. Virol J. 2012;9(1):1-12.
11. Lipipun V, Kurokawa M, Suttisri R, Taweechotipatr P, Pramyothin P, Hattori M, et al. Efficacy of Thai medicinal plant extracts against herpes simplex virus type 1 infection in vitro and in vivo. Antiviral Res. 2003;60(3):175-80.
12. Malik F, Singh J, Khajuria A, Suri KA, Satti NK, Singh S, et al. A standardized root extract of Withania somnifera and its major constituent withanolide-A elicit humoral and cell-mediated immune responses by up regulation of Th1-dominant polarization in BALB/c mice. Life Sci. 2007;80(16):1525-38.
13. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63.
14. Kurokawa M, Ochiai H, Nagasaka K, Neki M, Xu H, Kadota S, et al. Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antiviral Res. 1993;22(2-3):175-88.
15. Owlia P, Saderi H, Aghaee H, Zayeri F. The effect of Myrtus communis L. essential oil on treatment of Herpes simplex infection in animal model. Iran J Med Aromatic Plants Res. 2007;23(2):157-65.
16. Oberman F, Panet A. Inhibition of transcription of herpes simplex virus immediate early genes in interferon-treated human cells. J Gen Virol. 1988;69(6):1167-77.
17. Bouley DM, Kanangat S, Rouse BT. The role of the innate immune system in the reconstituted SCID mouse model of herpetic stromal keratitis. Clin Immunol immunopathol. 1996;80(1):23-30.
18. Paladino P, Mossman KL. Mechanisms employed by herpes simplex virus 1 to inhibit the interferon response. J Interferon Cytokine Res. 2009;29(9):599-608.
19. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 2003;8(3):223-46.
20. Horiuchi Y. Th1 regulatory events by infectious pathogens, herpes zoster and herpes simplex viruses: prospects for therapeutic options for atopic eczema. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2022;39(4):662-7.
21. Billiau A, Heremans H, Vermeire K, Matthys P. Immunomodulatory Properties of Interferon‐γ: An Update a. Ann N Y Acad Sci. 1998;856(1):22-32.
22. Boeren M, Meysman P, Laukens K, Ponsaerts P, Ogunjimi B, Delputte P. T cell immunity in HSV-1-and VZV-infected neural ganglia. Trends Microbiol. 2023;31(1):51-61.
23. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help. Nature. 2009;462(7272):510-3.
24. O’Neil TR, Hu K, Truong NR, Arshad S, Shacklett BL, Cunningham AL, et al. The role of tissue resident memory CD4 T cells in herpes simplex viral and HIV infection. Viruses. 2021;13(3):359.
25. Kumamoto Y, Mattei LM, Sellers S, Payne GW, Iwasaki A. CD4+ T cells support cytotoxic T lymphocyte priming by controlling lymph node input. Proc Natl Acad Sci U S A. 2011;108(21):8749-54.
26. Rajasagi NK, Kassim SH, Kollias CM, Zhao X, Chervenak R, Jennings SR. CD4+ T cells are required for the priming of CD8+ T cells following infection with herpes simplex virus type 1. J Virol. 2009;83(10):5256-68.
27. Gmyrek GB, Predki P, Gershburg E, Carr DJ. Noncognate Signals Drive Enhanced Effector CD8+ T Cell Responses through an IFNAR1-Dependent Pathway after Infection with the Prototypic Vaccine, 0ΔNLS, against Herpes Simplex Virus 1. J Virol. 2022;96(6):e01724-21.
28. Larsen H, Russell R, Rouse B. Recovery from lethal herpes simplex virus type 1 infection is mediated by cytotoxic T lymphocytes. Infect Immun. 1983;41(1):197-204.
29. Wang Y-S, Liu D, Wang X, Luo Q-L, Ding L, Fan D-Y, et al. Rasmussen’s encephalitis is characterized by relatively lower production of IFN-β and activated cytotoxic T cell upon herpes viruses infection. J Neuroinflammation. 2022;19(1):1-15.

留言 (0)

沒有登入
gif